Researchers at Massachusetts General Hospital (MGH) who previously developed a blood test for mutations in a gene linked to gliomas, the most common type of adult brain tumour, have now applied their technology to detect additional mutations, in this case in the gene that codes for epidermal growth factor receptor (EGFR).
The advance, which is described in a study published in Clinical Cancer Research, provides clinicians with a powerful tool to detect the presence of gliomas, characterise the tumour, and monitor their status after treatment.
The team’s test is a form of liquid biopsy that detects pieces of tumour cells’ genetic material—called mRNA—that are circulating in the blood.
A previous study first reported the technique, a highly optimised novel digital droplet polymerase chain reaction (ddPCR) blood test, for accurately detecting and monitoring the presence of two mutations of the gene TERT, which is commonly mutated in glioma tumour.
After further tailoring their technique to detect mRNA produced from a mutated EGFR gene called EGFRvIII that is often present in especially aggressive gliomas, the investigators determined the prevalence of EGFRvIII mRNA in glioma tumour tissue from 37 tumour tissue samples, and they tested their blood test in plasma samples from 30 patients with gliomas with tissue-confirmed EGFRvIII, 10 patients with gliomas with no EGFR mutations, and 14 healthy controls.
The team reported that the blood test had an overall sensitivity (ability to detect the presence of EGFRvIII) of 72.8% and a specificity (ability to detect the absence of EGFRvIII) of 97.7%.
“There is a real need to make brain tumour diagnosis less invasive than the current technique of tissue biopsy. This research demonstrates that it is now feasible to diagnosis a brain tumour via a blood test for one of the most common mutations detected in brain tumour,” says co–senior author Leonora Balaj, PhD, an investigator at MGH’s Brain tumour Research Center and an assistant professor of Neurosurgery at Harvard Medical School.
The technology could also be used to determine which patients are most likely to benefit from drugs targeting the EGFRvIII protein on cancer cells.
“Current studies involving CAR-T immune cells are aimed at targeting this surface marker. A blood-based assay for EGFRvIII would allow to stratify patients who would be eligible for potential clinical trials as well as monitor the response to the therapeutic using a simple blood test,” says co–senior author Bob S. Carter, MD, PhD, chair of the Department of Neurosurgery at MGH and the William and Elizabeth Sweet Professor of Neurosurgery at Harvard Medical School.
The scientists note that their EGFR and TERT tests will require additional studies to evaluate their performance in larger groups of patients; however, combining different mutation assays represents a promising strategy to more accurately diagnose gliomas, monitor tumour progression, and assess response to therapy.
The technology could also be applied to a range of other cancer types that carry mutations in these and other genes.
Source: Massachusetts General Hospital
We are an independent charity and are not backed by a large company or society. We raise every penny ourselves to improve the standards of cancer care through education. You can help us continue our work to address inequalities in cancer care by making a donation.
Any donation, however small, contributes directly towards the costs of creating and sharing free oncology education.
Together we can get better outcomes for patients by tackling global inequalities in access to the results of cancer research.
Thank you for your support.